Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 24, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 300,000 ordinary shares of 25 pence each.
- Purchase Price: 1,489.71 pence per share.
- Treasury Shares Held: 201,691,678 shares (post-transaction).
- Shares in Issue: 5,785,465,815 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 300,000 share repurchase against the stated price of 1,489.71 pence.
- Confirm the updated total number of shares in issue (5,785,465,815) in subsequent filings.
- Review the remaining authorization limit for share buybacks under the May 17, 2006 shareholder resolution.